Connect with Us
LP Login

Français

Businesses
- Overview
- Private Equity
- Credit
- Healthcare
- Venture
- SPAC
- Real Estate
- Private Wealth
About Us
- Who We Are
- Board of Directors
People
- Team
- Advisors
Portfolio
Responsibility
Insights
News and Events

Businesses
- Overview
- Private Equity
- Credit
- Healthcare
- Venture
- SPAC
- Real Estate
- Private Wealth
About Us
- Who We Are
- Board of Directors
People
- Team
- Advisors
Portfolio
Responsibility
Insights
News and Events

Sagard

Businesses
- Overview
- Private Equity
- Credit
- Healthcare
- Venture
- SPAC
- Real Estate
- Private Wealth
About Us
- Who We Are
- Board of Directors
People
- Team
- Advisors
Portfolio
Responsibility
Insights
News and Events

Businesses
- Overview
- Private Equity
- Credit
- Healthcare
- Venture
- SPAC
- Real Estate
- Private Wealth
About Us
- Who We Are
- Board of Directors
People
- Team
- Advisors
Portfolio
Responsibility
Insights
News and Events

Connect With Us LP Login

Communiquez avec nous Connexion

Français

Sagard Signs $50 Million Royalty Deal for Athenex Cancer Drug | Wall Street Journal

August 06, 2020

Tags

Connect with us

Businesses
Overview
Private Equity
Credit
Healthcare
Venture
SPAC
Real Estate
Private Wealth

About Sagard
Who We Are
Firm History
Portfolio
Responsibility
Board of Directors

People
Team
Advisors

Media
Insights
News and Events

Montreal

1172 Sherbrooke Ouest
Montréal, QC H3A 1H6
Canada
+1 (514) 286-6248

New York

280 Park Avenue 29th Floor East
New York, NY 10017
United States
+1 (212) 380-5605

Florida

4850 Tamiami Trail North, Suite 301

Naples, FL 34103

United States

Toronto

161 Bay Street, Suite 5000
Toronto, ON M5J 2S1
Canada
+1 (416) 607-2250

Paris

49/51, Avenue George V
75008 Paris
France
+33 (0)1 53 83 30 00

© 2021 Sagard. All rights reserved.

Connect With Us Terms and Conditions Privacy Policy Sagard EMD Inc.LP Login